Understanding Evaluation of Patient Information Sheets by User Testing Method
Study Details
Study Description
Brief Summary
The purpose of this randomized, open label, crossover, single site study is to compare the PISs of two Multiple Sclerosis clinical trials to elucidate potential aspects of the given written information that could impact on the smooth running of the studies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The participation to a clinical trial is based on two forms of information: the spoken information, usually given by a clinician during the enrolment meeting, and the written information, reported on the Participant Information Sheet (PIS). Numerous studies performed to improve and enhance informed consent, have used different methods to evaluate the quality of the given information such as: interview, checklist, questionnaire, readability formulae. Even if these tools can be useful, they show evident limits in detecting the real efficacy of the proposed consent form in terms of the patient's comprehension.
User Testing (UT) is a method originally developed in the 1990 in Australia, to assess how a text about medicinal products performs with its intended users and not just its content.
Generally, the UT is based on an iterative 4-step process in a cohort of participants (the target group):
-
individual reading of the text;
-
individual questionnaire for a quantitative and qualitative evaluation;
-
a brief semi-structured interview to each participant;
-
a text revision to address any problems identified from participant feedback; Then the revised document is tested again with a second cohort and this iterative process continues until all issues with the document are resolved. However, a methodological issue not yet explored is whether the UT could be used to compare two different PISs, in order to elucidate aspects that could be involved in improving or worsening the understanding of a PIS.
UT has been recently used to evaluate the PIS belonging to phase I and phase III clinical trials (CT) in Myeloid Leukemia, immunomodulatory therapy and for poor responders in vitro fertilization. To date, in no case the UT method has been tested in patients affected by chronic disease like Multiple Sclerosis (MS).
We want to apply the UT approach to highlight the critical issues and communication difficulties present in PISs used in MS clinical trials.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Prevalence of CCSVI in MS Subjects with prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases - PIS User Testing |
Other: PIS User Testing
PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):
individual reading of the text;
individual questionnaire for a quantitative and qualitative evaluation;
a brief semi-structured interview to each participant;
a text revision to address any problems identified from participant feedback.
|
| Other: BVD Exploited Against MS Subjects suffering from Brain venous drainage exploited against Multiple Sclerosis - PIS User Testing |
Other: PIS User Testing
PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):
individual reading of the text;
individual questionnaire for a quantitative and qualitative evaluation;
a brief semi-structured interview to each participant;
a text revision to address any problems identified from participant feedback.
|
Outcome Measures
Primary Outcome Measures
- percentage of found and understood-if-found items [1 day]
percentage
Secondary Outcome Measures
- understanding of the text expressed by subject [1 day]
Visual Analogue Scale (VAS)
Eligibility Criteria
Criteria
Inclusion Criteria: PwMS (60%) and Caregivers (40%):
for PwMS:
-
18 years or older;
-
MS diagnosis according to McDonald criteria;
-
Informed consent to the present study for caregivers:
-
18 years or older;
-
in being a person who takes care of a PwMS;
-
Informed consent to the present study
Exclusion Criteria:
- not having taken part in one of the following trials evaluated in the present study: A) Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases (PIS-A); B) BRAin VEnous DRainage Exploited Against Multiple Sclerosis (PIS-B).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fondazione Italiana Sclerosi Multipla (FISM) | Genova | Liguria | Italy | |
| 2 | Opera Contract Research Organization SRL | Timisoara | Timis | Romania | 300209 |
Sponsors and Collaborators
- Fondazione Italiana Sclerosi Multipla
- Opera CRO, a TIGERMED Group Company
Investigators
- Study Director: Mario Alberto Battaglia, Prof., Fondazione Italiana Sclerosi Multipla (FISM), Genova , (Italy)
Study Documents (Full-Text)
None provided.More Information
Additional Information:
- Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases (COSMO), ClinicalTrials.gov Identifier: NCT01384825
- BRAin VEnous DRainage Exploited Against Multiple Sclerosis (BRAVE-DREAMS), ClinicalTrials.gov Identifier: NCT01371760
Publications
- Knapp P, Raynor DK, Silcock J, Parkinson B. Can user testing of a clinical trial patient information sheet make it fit-for-purpose?--a randomized controlled trial. BMC Med. 2011 Jul 21;9:89. doi: 10.1186/1741-7015-9-89.
- Knapp P, Raynor DK, Silcock J, Parkinson B. Performance-based readability testing of participant information for a Phase 3 IVF trial. Trials. 2009 Sep 1;10:79. doi: 10.1186/1745-6215-10-79.
- Knapp P, Raynor DK, Silcock J, Parkinson B. Performance-based readability testing of participant materials for a phase I trial: TGN1412. J Med Ethics. 2009 Sep;35(9):573-8. doi: 10.1136/jme.2008.026708.
- Raynor DK. User testing in developing patient medication information in Europe. Res Social Adm Pharm. 2013 Sep-Oct;9(5):640-5. doi: 10.1016/j.sapharm.2013.02.007. Epub 2013 Apr 10.
- FISM 2012R2